rabeprazole / Generic mfg. - LARVOL DELTA

Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study. (PubMed, Drugs Real World Outcomes) - "This real-world study highlighted utilization patterns of PPIs and demonstrated that all PPIs are effective and well-tolerated in managing APD symptoms in patients with comorbidities. Pantoprazole was the most co-prescribed and preferred PPI amongst the prescribed PPIs. These findings provide real-world insights into how PPIs are utilized in Indian patients with APD and comorbidities and may help clinicians make informed decisions when selecting an appropriate PPI in routine practice."

Journal • Real-world evidence

Treatment Adherence in Laryngopharyngeal Reflux: A Prospective, Blinded Study of Influencing Factors and Their Impact on Symptom Improvement. (PubMed, J Voice) - "In this study, married participants, non-working participants, non-shift workers, and participants without multiple medications complied better to medication use. Low initial adherence followed by time-dependent improvement suggests that early counseling is critical for long-term patient compliance."

Journal

Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan. (PubMed, Drug Healthc Patient Saf) - "Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Adverse events associated with drug-related thiamine deficiency: A pharmacovigilance study. (PubMed, JPEN J Parenter Enteral Nutr) - "This pharmacovigilance analysis identifies safety signals linking specific medications with thiamine deficiency, potentially mediated by mechanisms such as transport inhibition and metabolic interference. These findings highlight the importance of clinical vigilance and the consideration of thiamine monitoring in high-risk patients to mitigate the risk of neurological complications."

Adverse events • Journal • Addiction (Opioid and Alcohol) • CNS Disorders

Genetic causal association between kidney stones and proton pump inhibitors. (PubMed, Int Urol Nephrol) - "In conclusion, this study found no evidence supporting a causal role for PPIs in increasing kidney stone risk, providing genetic-level evidence to support the safe use of PPIs in patients with gastric ulcers or gastroesophageal reflux disease."

Journal • Chronic Kidney Disease • Gastroenterology • Gastroesophageal Reflux Disease • Metabolic Disorders • Nephrology • Peptic Ulcer • Renal Calculi • Renal Disease • ATP4A

EZ-STAR: Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: Yonsei University

New P4 trial

Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience. (PubMed, Allergol Immunopathol (Madr)) - "Skin testing is a valuable tool in predicting hypersensitivity reactions associated with PPIs. Although rare, hypersensitivity reactions may occur in patients with negative skin tests."

Journal • Retrospective data • Allergy • Immunology

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (clinicaltrials.gov) - P1 | N=41 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2026 ➔ Apr 2026 | Trial primary completion date: Jul 2026 ➔ Feb 2026

Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials. (PubMed, EClinicalMedicine) - "At 8 weeks, zastaprazan 20 mg, vonoprazan 20 mg, and esomeprazole 40 mg demonstrated moderate-certainty superiority over rabeprazole 20 mg and omeprazole 20 mg with RDs ranging from 0.05 to 0.11, while only vonoprazan 20 mg demonstrated moderate-certainty benefit versus lansoprazole 30 mg (RD: 0.04)...Vonoprazan 20 mg and rabeprazole-ER 50 mg demonstrated moderate-certainty benefit compared with pantoprazole 40 mg (RDs: 0.12 and 0.09, respectively).At 24 weeks, vonoprazan 10 mg and 20 mg showed moderate-to-high-certainty benefit versus lansoprazole 15 mg (RDs: -0.11 and -0.13, respectively), while in direct comparisons, esomeprazole 20 mg outperformed lansoprazole 15 mg and pantoprazole 20 mg, with approximately 40-50% relative reductions in recurrence...Comparative trials evaluating newer P-CABs against optimized PPI strategies, including twice-daily dosing, are needed to evaluate efficacy and long-term safety, particularly with respect to hypergastrinemia and infection..."

Journal • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Feb 2026 ➔ Aug 2026 | Trial primary completion date: Feb 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date

Effect of a WeChat-based medication reminder platform on Helicobacter pylori therapy. (PubMed, Front Med (Lausanne)) - "All patients received a 14-day quadruple regimen consisting of amoxicillin, furazolidone, rabeprazole, and bismuth potassium citrate. This digital intervention offers a promising strategy for enhancing the effectiveness of H. pylori eradication therapy and optimizing patient outcomes in clinical practice. Large-scale, multicenter randomized controlled trials (RCTs) are required to further confirm its effectiveness and popularize its application."

Journal • Infectious Disease

Amino acid derived chiral thioureas: design, synthesis and applications as NMR resolving agents for enantioselective recognition. (PubMed, Org Biomol Chem) - "The scope of enantiodiscrimination was further extended to a broad range of analytes, including chiral carboxylic acids, phosphoric acid derivatives, dihydropyrimidinones, sulfoxides, N-Boc amino alcohols and proton pump inhibitors such as Omeprazole and Rabeprazole. These findings establish amino acid based chiral thioureas as versatile receptors for molecular recognition and enantiodiscrimination of diverse substrates."

Journal

Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening. (PubMed, Bioorg Chem) - "Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change (clinicaltrials.gov) - P=N/A | N=83 | Completed | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • Infectious Disease

LOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study. (PubMed, J Clin Med) - " Low-dose rabeprazole was associated with reduced GI complications in patients receiving chronic antithrombotic therapy, with a favorable safety profile and high adherence. Further studies with larger and broader populations are required to confirm these findings."

Journal • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Peptic Ulcer

Post-translational modifications of triosephosphate isomerase reveal metabolic vulnerabilities in T-ALL. Effect of combining dichloroacetic acid and the PPI rabeprazole. (PubMed, Biochem J) - "Finally, combined dichloroacetate-rabeprazole treatment induced extensive apoptotic death in Jurkat cells while sparing normal lymphocytes. These findings identify post-translational modifications-bearing TPI isoforms as selective metabolic vulnerabilities in Jurkat cells and support the potential repurposing of thiol-modifying agents, particularly, rabeprazole, as targeted antileukemic strategies."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

Efficacy of vonoprazan fumarate in the treatment of peptic ulcers (ChiCTR) - P=N/A | N=600 | Completed | Sponsor: Xiamen Humanity hospital; Xiamen Humanity hospital

New trial • Gastroenterology • Peptic Ulcer

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (clinicaltrials.gov) - P=N/A | N=552 | Recruiting | Sponsor: Kaohsiung Medical University

New trial • Infectious Disease

The Efficacy and Safety of Anaprazole Quadruple Therapy Versus Rabeprazole Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (ChiCTR) - P=N/A | N=220 | Not yet recruiting | Sponsor: NanJing First Hospital; NanJing First Hospital

New trial • Gastrointestinal Disorder • Infectious Disease

Analysis of the efficacy and safety of magaldrate granules quadruple therapy in the treatment of Helicobacter pylori infection (PubMed, Zhonghua Yi Xue Za Zhi) - "No statistically significant differences were found in the incidence rates of these adverse events between Group A and Control Group, or Group B and Control Group (all P>0.05). The quadruple therapy combining magaldrate granules with rabeprazole, amoxicillin, and clarithromycin demonstrates good Hp eradication efficacy and high safety."

Journal • Gastrointestinal Disorder • Infectious Disease • Pain

Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling. (PubMed, mSystems) - P=N/A | "The study aimed to evaluate the efficacy of a multi-strain probiotic (Lihuo) with rabeprazole in GERD and its impact on gut microbiota and metabolome...Strong correlations linked microbial shifts to metabolic and clinical improvements. This study demonstrates that adjunctive probiotic therapy enhances symptom control and supports microbial-metabolic homeostasis in GERD.CLINICAL TRIALSThis study is registered with the Chinese Clinial Trial Registry as ChiCTR2000038409."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Assessment of diverse proton pump inhibitor combined with bismuth quadruple regimens and risk factors for Helicobacter pylori eradication in China: A retrospective single-center study. (PubMed, Arab J Gastroenterol) - "The eradication rates across various PPI-based quadruple regimens were comparable; however, the regimen comprising amoxicillin and clarithromycin demonstrated low efficacy and is not advised in settings with high clarithromycin resistance. Among the effective therapeutic regimens, the esomeprazole-based regimen exhibited a slightly higher eradication rate."

Journal • Retrospective data • Infectious Disease

A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer. (PubMed, J Adv Res) - "Trastuzumab profoundly improves outcomes of Her2+ breast cancer (BC) patients, but eventual drug resistance is inevitable...Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2+ BC by reducing tumor EVs...Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2+ BC therapy."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CD8 • CXCL9 • HER-2

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (clinicaltrials.gov) - P=N/A | N=390 | Recruiting | Sponsor: Kaohsiung Medical University | N=780 ➔ 390

Enrollment change • Infectious Disease

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital

New P1 trial • Gastroenterology